Document is current
Any future updates will be listed below
-
Authors
Hertz, Charles https://orcid.org/0009-0003-7525-3387
Spyrou, Nikolaos
Hoffman, Ronald https://orcid.org/0000-0001-6564-6732
Cimen Bozkus, Cansu
Bhardwaj, Nina
Tremblay, Douglas https://orcid.org/0000-0002-4719-7192
Kremyanskaya, Marina
Mascarenhas, John https://orcid.org/0000-0002-8400-0483
- License Information
-
More Information
Article History
Received: 8 June 2026
Revised: 27 July 2026
Accepted: 12 August 2026
First Online: 18 August 2026
Ethics
Competing interests: CH: declares no competing interests. NS: declares no competing interests. JM: reports research funding (payments to institution) from Incyte, Novartis, BMS, AbbVie, SOBI, Geron, Kartos, Karyopharm, DISC, Ajax, PharmaEssentia, and Italfarmaco Spa; consulting fees from Incyte, Novartis, BMS, AbbVie, SOBI, Geron, Karyopharm, DISC, PharmaEssentia, Italfarmaco Spa, Merck, Sumitomo, Galecto, GSK, and Blueprint Medicines; and stock or stock options in Cogent. RH: declares no competing interests. CCB: declares no competing interests. NB: reports a patent pending. MK: reports consulting fees from Incyte, Morphosys, and GSK. DT: reports research funding (payments to institution) from Sobi, Sumitomo, Blueprint, Geron, Oryzon, and Cogent Biosciences; and consulting fees from Sobi, Refined Oncology, Ipsen, AbbVie, PharmaEssentia, Geron, GSK, and Cogent Biosciences.
